Drug Type Small molecule drug |
Synonyms EC-905, JLP-1207, Vesomni + [1] |
Target |
Mechanism M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists), α1A-AR antagonists(Alpha-1a adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date NL (07 Oct 2013), |
Regulation- |
Molecular FormulaC27H32N2O6 |
InChIKeyRXZMMZZRUPYENV-VROPFNGYSA-N |
CAS Registry242478-38-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Lower Urinary Tract Symptoms | NL | 07 Oct 2013 |
Phase 3 | 1,067 | jobsqtogmr(qquhnvizsf) = tjndpxvqua waqwigpvhb (igcasozsuq, vkcyhgpnhe - vrtooozqax) View more | - | 22 Jan 2016 | |||
Phase 3 | 1,334 | Placebo tamsulosin hydrochloride OCAS 0.4 mg+Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg (Placebo) | jdqspfossm(xcdvrdcrgv) = ohvpnchleo sqkswkyltk (bsefmhsdtm, acgodoookj - kltvaifjvu) View more | - | 17 Dec 2015 | ||
jdqspfossm(xcdvrdcrgv) = dsekpqdtvw sqkswkyltk (bsefmhsdtm, dfrfrfoieo - rbdpzbavjk) View more | |||||||
Phase 3 | 1,066 | solifenacin and tamsulosin oral | zakhdxfpge(pymdujnhhc) = Urinary retention occurred in 13 of 1208 (1.1%) patients receiving one or more FDCs in NEPTUNE and/or NEPTUNE II; 8 (0.7%) required catheterisation (acute urinary retention [AUR]) dszhtnirtz (bepzyzhhuc ) | Positive | 01 Feb 2015 | ||
Phase 4 | 70 | (Solifenacin) | gehbppjggc(lulygtvscz) = obqhvxdxob tqzxdgplwn (bvlvwsbfcc, gstnzssrri - ebvcldvdpo) View more | - | 27 Jan 2015 | ||
(Solifenacin Plus Tamsulosin) | gehbppjggc(lulygtvscz) = tznrjkkqmv tqzxdgplwn (bvlvwsbfcc, wwmcxpxpji - ltdwvsptov) View more |